Roche Unveils $50 Billion Five-Year US Investment Plan to Expand Manufacturing and R&D
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced a five-year investment plan totaling...
China Medical System Announces Spin-off of Dermavon for HKEX IPO
China Medical System Holdings Limited (CMS; HKG: 0867) has announced the spin-off of its dermatology-focused...
BMS’s Cobenfy Shows Promise in Phase III ARISE Trial for Schizophrenia
Bristol-Myers Squibb (BMS, NYSE: BMY) has announced top-line results from the Phase III ARISE trial...
CSPC Gains NMPA Approval for Phase III Trial of Prusogliptin/Metformin FDC
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has secured approval from the National Medical Products...
CSPC Pharmaceutical Gains FDA IND Clearance for JMT203 in Cancer Cachexia
China-based CSPC Pharmaceutical Group Limited (HKG: 1093) has obtained Investigational New Drug (IND) clearance from...
Grand Pharma Secures NMPA Approval for Fluticasone Nasal Spray
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has obtained marketing authorization from China’s National...
Biokin Receives NMPA Approval for CD33 ADC in AML Trial
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has received approval...
Fujifilm Diosynth Secures $3 Billion US Manufacturing Pact with Regeneron
FUJIFILM Diosynth Biotechnologies (FDB), a leading global contract development and manufacturing organization (CDMO) specializing in...
Hotgen Biotech Injects RMB 300 Million into Subsidiary Sungen Bio for Biologic R&D
China’s Hotgen Biotech Co., Ltd (SHA: 688068) has announced a strategic capital injection plan, partnering...
NMPA Issues 91st Batch of Reference Standards for Generic Drug Quality Evaluation
The National Medical Products Administration (NMPA) has released the 91st batch of reference standards for...
United InnoMed Closes RMB 100 Million Series B+ Funding for Heart Failure Devices
Shanghai-based United InnoMed, a developer of Class III active implantable medical devices, has closed a...
Novocure Wins CE Mark for Optune Lua in Metastatic NSCLC Treatment
Switzerland-based Novocure (NASDAQ: NVCR), the developer of Tumor Treating Fields (TTFields) for cancer therapy, has...
JW Therapeutics Enters Licensing Pact with Juno Therapeutics for sLVV Process
China-based JW Therapeutics (HKG: 2126), co-founded by Juno Therapeutics Inc. (a Bristol-Myers Squibb company) and...
iMBIORAY Gains NMPA Approval for Phase IITrial of IBR854 in Advanced RCC
Hangzhou-based cancer immunotherapy specialist iMBIORAY has received approval from China’s National Medical Products Administration (NMPA)...
Ascletis Pharma Announces Positive Phase Ib Results for ASC30 in Obesity Treatment
China-based Ascletis Pharma Inc. (HKG: 1672) has announced positive top-line results from a Phase Ib...
Delonix Partners with WuXi Vaccines to Advance OMV Plus Platform for Bacterial Vaccines
China-based Delonix Bioworks Ltd., a developer of genetically engineered bacterial vaccines, has entered into a...
Akeso’s Ivonescimab Shows Strong Results in Phase III Trial for Sq-NSCLC
China-based Akeso, Inc. (HKG: 9926) announced strongly positive results from the regulatory Phase III AK112-306/HARMONi-6...
BMS Secures NMPA Approval for Opdivo in Resectable NSCLC Neoadjuvant Therapy
Bristol-Myers Squibb (BMS, NYSE: BMY) has announced additional indication approval from China’s National Medical Products...
AstraZeneca’s Ultomiris Approved in China for Generalized Myasthenia Gravis
UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) has announced that the National Medical Products Administration (NMPA)...
Zai Lab’s Augtyro NDA Accepted by China’s NMPA for NTRK Fusion Solid Tumors
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced that the supplemental New Drug...